BofA is moving to No Rating on Sage Therapeutics (SAGE) after the company announced it has received an unsolicited, nonbinding acquisition proposal from partner Biogen (BIIB) for $7.22 per share. Sage is no longer trading on its fundamentals following the news, argues the analyst, who looks for further details on the outcome of the proposal.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Morning Movers: Intra-Cellular surges following deal to be bought by J&J
- SAGE Therapeutics Outlines 2025 Strategy and Acquisition Proposal
- Sage Therapeutics confirms $7.22 per share acquisition proposal from Biogen
- Sage Therapeutics price target raised to $5 from $4 at RBC Capital
- Sage Therapeutics price target lowered to $9 from $26 at Piper Sandler